阿立哌唑与利培酮治疗女性首发精神分裂症对照研究

目的评价阿立哌唑与利培酮治疗女性首发精神分裂症患者的临床疗效和安全性。方法将100例精神分裂症患者随机分为阿立哌唑组与利培酮组各50例，分别口服阿立哌唑组和利培酮治疗，观察12周。于治疗前及治疗2周、4周、6周、8周、12周末采用阳性与阴性症状量表评定l晦床疗效，副反应量表评定不良反应。结果两组治疗第2周末起，阳性与阴性症状量表总分较治疗前有显著下降（P〈0．01），4周末起阴性症状因子分较治疗前显著下降（P〈0．05），同期两组间评分均无显著性差异（P日〉O．05）；治疗12周末，阿立哌唑组显效率82．0％、有效率90．0％，利培酮组分别为80．0％、92．0％，两组疗效无显著性差异（P〉0．05）。治疗后两组不良反应均轻微，且阿立哌唑组患者治疗前后空腹血糖、体重指数、月经周期均无显著变化；利培酮组治疗后各项指标均较治疗前升高，其中空腹血糖及月经周期有极显著性差异（P〈0．01）；治疗后利培酮组空腹血糖及月经周期显著高于阿立哌唑组（P〈0．01）。结论阿立哌唑与利培酮治疗精神分裂症起效快，疗效显著且相当。但阿立哌唑安全性更高，对血糖、体重、内分泌影响较小，更适合应用于女性精神分裂症患者。

A controlled study of aripiprazole versus risperidone in the treatment of female first-episode shizophrenia

Objective To evaluate the clinical efficacy and safety of aripiprazole versus risperidone in the treatment of female first-episode shizophrenia. Methods 100 schizophrenics were randomly assigned to two groups of 50 patients each, took orally aripiprazole or risperidone respectively for 12 weeks. Clinical efficacies were assessed with the Positive and Negative Syndromes Scale （PANSS） and adverse raections with the Treatment Emergent Symptoms Scale （TESS） before treatment and at the end of the 2nd , 4th , 6th , 8th and 12th week. Results The total scores of the PANSS lowered more significantly sing the end of the 2nd week（P〈0.01） and so did negative socres singce the end of the 4th week（P〈0.05） compared with pretreatment, and there were no significant differences in synchronization group comparisons（all P〈0.05）. At the end of the 12th week, obvious effective and effective rates were 82.0% and 90.0% in the aripiprazole and 80.0% and 92.0% in the risperidone group respectively,which showed no significant differences（P〈0.05）. After treatment, adverse raections of both groups were mild, and there were no notable changes in blood-fasting sugar, body mass index and menstrual cycle compared with pretreatment in the aripiprazole group; all indexes heightened, especially blood-fasting sugar and menstrual cycle changed more significantly（P〈0.01） in the risperidone group; after treatment, blood-fasting sugar and menstrual cycle were significantly higher in the risperidone than in the aripiprazole group（P〈0.01）. Conclusion Both aripiprazole and risperidone take effects rapidly and have notable and equivalent efficacies in schizophrenia. But aripiprazole has higher safety and less influence on blood sugar, body weight and endocrine, and is more suitable for female shizophrenics.